Vascular Optimized Radiotherapy for Prostate Cancer and Erectile Function
This study is testing a special type of radiation therapy called neurovascular sparing stereotactic body radiation therapy (SBRT) for men with prostate cancer. SBRT uses highly focused X-rays to treat the cancer in five high doses. The goal is to protect the nerves and blood vessels around the prostate that are important for erectile function, as these can sometimes be affected by standard radiation. Researchers will measure sexual function using a questionnaire (EPIC-26) 24 months after treatment to see how well this technique works. You may be able to join if you are a man aged 18 or older with confirmed, localized prostate cancer. The study plans to enroll 200 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 200 male participants aged 18 and older.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your sexual function will be measured 24 months after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Amar Kishan, MD · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Expanded Prostate Cancer Index Composite (EPIC-26) sexual function Questionnaire24 months
The primary endpoint is clinically relevant (≥24 point) decline in EPIC-26 sexual function domain scores at 24 months following treatment in patients randomized to NV-sparing SBRT relative to patients randomized to conventional SBRT without explicit NV-sparing.